Adding of sitagliptin phosphate hydrate to combination therapy with pegylated interferon alpha 2b and ribavirin for patients with chronic hepatitis C and diabetes mellitus
Not Applicable
- Conditions
- Patients with chronic hepatitis C and hyperglycemia
- Registration Number
- JPRN-UMIN000003775
- Lead Sponsor
- Department of Hepatology, Osaka City University
- Brief Summary
Enrolled patients were few. Now, new anti-HCV drugs were available for patients with chronic hepatitis C. We decide the discontinuation of the present study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
pregnant woman drug allergy insulin medication depression autoimmune diseases malignant diseases
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sustained viral response of HCV
- Secondary Outcome Measures
Name Time Method Safety